1. Home
  2. NBTX vs RFAI Comparison

NBTX vs RFAI Comparison

Compare NBTX & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBTX
  • RFAI
  • Stock Information
  • Founded
  • NBTX 2003
  • RFAI 2024
  • Country
  • NBTX France
  • RFAI Singapore
  • Employees
  • NBTX N/A
  • RFAI N/A
  • Industry
  • NBTX Biotechnology: Pharmaceutical Preparations
  • RFAI
  • Sector
  • NBTX Health Care
  • RFAI
  • Exchange
  • NBTX Nasdaq
  • RFAI NYSE
  • Market Cap
  • NBTX 167.8M
  • RFAI 157.3M
  • IPO Year
  • NBTX 2020
  • RFAI 2024
  • Fundamental
  • Price
  • NBTX $4.48
  • RFAI $10.53
  • Analyst Decision
  • NBTX Strong Buy
  • RFAI
  • Analyst Count
  • NBTX 1
  • RFAI 0
  • Target Price
  • NBTX $8.00
  • RFAI N/A
  • AVG Volume (30 Days)
  • NBTX 9.1K
  • RFAI 4.3K
  • Earning Date
  • NBTX 04-02-2025
  • RFAI 01-01-0001
  • Dividend Yield
  • NBTX N/A
  • RFAI N/A
  • EPS Growth
  • NBTX N/A
  • RFAI N/A
  • EPS
  • NBTX N/A
  • RFAI 0.32
  • Revenue
  • NBTX N/A
  • RFAI N/A
  • Revenue This Year
  • NBTX N/A
  • RFAI N/A
  • Revenue Next Year
  • NBTX $221.06
  • RFAI N/A
  • P/E Ratio
  • NBTX N/A
  • RFAI $32.95
  • Revenue Growth
  • NBTX N/A
  • RFAI N/A
  • 52 Week Low
  • NBTX $2.76
  • RFAI $10.00
  • 52 Week High
  • NBTX $6.00
  • RFAI $10.60
  • Technical
  • Relative Strength Index (RSI)
  • NBTX 51.68
  • RFAI N/A
  • Support Level
  • NBTX $4.18
  • RFAI N/A
  • Resistance Level
  • NBTX $5.76
  • RFAI N/A
  • Average True Range (ATR)
  • NBTX 0.24
  • RFAI 0.00
  • MACD
  • NBTX -0.06
  • RFAI 0.00
  • Stochastic Oscillator
  • NBTX 21.69
  • RFAI 0.00

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

About RFAI RF ACQUISITION CORP II

RF Acquisition Corp II is a blank check company.

Share on Social Networks: